SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), a biopharmaceutical
company developing cancer stem cell-related therapeutics, today announced it
will be featured as a presenting company at the 15th Annual Rodman & Renshaw
Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The
conference is being held September 8-10, 2013, at the Millennium Broadway Hotel
in New York City. Dr. Niclas Stiernholm, the CEO of Stem Cell Therapeutics, will
provide an overview of the Company's business during the live presentation and
will be available to participate in one-on-one meetings with investors who are
registered to attend the conference.




      Event: 15th Annual Rodman & Renshaw Global Investment Conference      
      Date: September 9, 2013                                               
      Time: 2.50 pm (Eastern Time)                                          
      Location: Room 7.01; Millennium Broadway Hotel in New York City       



About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT) is a biopharmaceutical company dedicated to
advancing cancer stem cell discoveries into novel and innovative cancer
therapies. Building on over half a century of leading and groundbreaking
Canadian stem cell research, the company is supported by established links to a
group of Toronto academic research institutes and cancer treatment centers,
representing one of the world's most acclaimed cancer research hubs. The Company
has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody
(mAb), which target two key immunoregulatory pathways that tumor cells exploit
to evade the host immune system. SIRPaFc is an antibody-like fusion protein that
blocks the activity of CD47, a molecule that is upregulated on cancer stem cells
in AML and several other tumors. The CD200 mAb is a fully human monoclonal
antibody that blocks the activity of CD200, an immunosuppressive molecule that
is overexpressed by many hematopoietic and solid tumors. SCT's clinical stage
programs include the recently in-licensed program focused on the structure of
tigecycline, which is currently being evaluated in a multi-centre Phase I study
in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non-cancer
stem cell asset that recently completed a 28-patient Phase I trial in
interstitial cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com.


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com


Investor Contact:
ProActive Capital
Jeff Ramson
+1 646-863-6519
jramson@proactivecapital.com


ProActive Capital
Kirin Smith
+1 646-863-6519
ksmith@proactivecapital.com

Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024